

Nicola Normanno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5821405/publications.pdf>

Version: 2024-02-01

274
papers

20,174
citations

17429

63
h-index

12258

133
g-index

280
all docs

280
docs citations

280
times ranked

23952
citing authors

#	ARTICLE	IF	CITATIONS
1	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
2	Epidermal growth factor-related peptides and their receptors in human malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 19, 183-232.	2.0	2,457
3	Epidermal growth factor receptor (EGFR) signaling in cancer. <i>Gene</i> , 2006, 366, 2-16.	1.0	1,744
4	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S17-S27.	1.5	580
5	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2011, 12, 594-603.	5.1	522
6	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 519-527.	12.5	391
7	The role of the EGFR signaling in tumor microenvironment. <i>Journal of Cellular Physiology</i> , 2008, 214, 559-567.	2.0	323
8	Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.. <i>Endocrine-Related Cancer</i> , 2003, 10, 1-21.	1.6	279
9	The ErbB Receptors and their Ligands in Cancer: An Overview. <i>Current Drug Targets</i> , 2005, 6, 243-257.	1.0	257
10	Implementing TMB measurement in clinical practice: considerations on assay requirements. <i>ESMO Open</i> , 2019, 4, e000442.	2.0	257
11	Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions. <i>Oncologist</i> , 2006, 11, 753-764.	1.9	245
12	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, 721-747.	1.6	242
13	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. <i>Annals of Oncology</i> , 2002, 13, 65-72.	0.6	240
14	Leptin signaling in breast cancer: An overview. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 956-964.	1.2	200
15	Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. <i>Oncologist</i> , 2009, 14, 378-390.	1.9	176
16	Guidance for laboratories performing molecular pathology for cancer patients. <i>Journal of Clinical Pathology</i> , 2014, 67, 923-931.	1.0	169
17	Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. <i>Oncogene</i> , 2005, 24, 5731-5741.	2.6	168
18	VEGF as a potential target in lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 959-966.	1.5	159

#	ARTICLE	IF	CITATIONS
19	EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey. <i>Journal of Thoracic Oncology</i> , 2015, 10, 438-445.	0.5	156
20	Epithelial to Mesenchymal Transition by TGF β -1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line. <i>PLoS ONE</i> , 2011, 6, e21548.	1.1	153
21	ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1682-1689.	0.5	151
22	The role of EGF-related peptides in tumor growth. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, d685.	3.0	141
23	Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells. <i>Molecular and Cellular Biology</i> , 2002, 22, 2586-2597.	1.1	139
24	Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. <i>Journal of Clinical Investigation</i> , 2003, 112, 575-587.	3.9	136
25	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. <i>Journal of Cellular Physiology</i> , 2006, 207, 420-427.	2.0	127
26	Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. <i>Journal of Cellular Physiology</i> , 2004, 201, 266-276.	2.0	126
27	Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665.	15.2	125
28	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action?. <i>Journal of Cellular Physiology</i> , 2003, 194, 13-19.	2.0	124
29	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. <i>Annals of Oncology</i> , 2015, 26, 1710-1714.	0.6	120
30	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018, 70, 1-8.	3.4	116
31	Expression of transforming growth factor β , amphiregulin and cripto-1 in human breast carcinomas. <i>British Journal of Cancer</i> , 1994, 69, 903-910.	2.9	114
32	The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer.. <i>Endocrine-Related Cancer</i> , 2000, 7, 199-226.	1.6	113
33	Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994, 29, 11-27.	1.1	112
34	Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 12501-12516.	0.8	112
35	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Erlotinib™) is independent of EGFR expression level. <i>Journal of Cellular Physiology</i> , 2004, 198, 259-268.	2.0	108
36	TGF- β 1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. <i>Cell Death and Disease</i> , 2013, 4, e620-e620.	2.7	108

#	ARTICLE	IF	CITATIONS
37	Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2014, 25, 1756-1761.	0.6	105
38	EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. <i>Lung Cancer</i> , 2017, 113, 37-44.	0.9	99
39	Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel. <i>PLoS ONE</i> , 2013, 8, e80478.	1.1	96
40	EGFR-targeted therapy. <i>Experimental Cell Research</i> , 2011, 317, 2765-2771.	1.2	94
41	Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. <i>Endocrine-Related Cancer</i> , 2005, 12, 471-482.	1.6	93
42	Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 3363-3370.	1.2	92
43	Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 2131-2138.	2.0	91
44	A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. <i>Cancer Research</i> , 2003, 63, 1192-7.	0.4	91
45	Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 3330-3335.	1.6	88
46	Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. <i>Oncogene</i> , 2000, 19, 5863-5871.	2.6	88
47	The role of EGF-related peptides in tumor growth. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, d685-707.	3.0	86
48	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. <i>Future Oncology</i> , 2015, 11, 1611-1623.	1.1	82
49	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 5-20.	1.4	82
50	Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 1995, 35, 293-297.	1.1	81
51	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
52	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	3.4	80
53	Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5158-5164.	3.2	79
54	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. <i>Oncotarget</i> , 2016, 7, 66595-66605.	0.8	78

#	ARTICLE	IF	CITATIONS
55	Regulation by Estrogen through the 5' Flanking Region of the Transforming Growth Factor β Gene. <i>Molecular Endocrinology</i> , 1991, 5, 1955-1963.	3.7	77
56	Role of Human Cripto-1 in Tumor Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2005, 97, 132-141.	3.0	76
57	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , 2016, 27, 1055-1061.	0.6	73
58	Angiogenesis Inhibitors in NSCLC. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2021.	1.8	73
59	Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. <i>Oncogene</i> , 2005, 24, 4094-4105.	2.6	70
60	Cripto-1: An Oncofetal Gene with Many Faces. <i>Current Topics in Developmental Biology</i> , 2005, 67, 85-133.	1.0	70
61	Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 27-37.	1.4	70
62	Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor β Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome. <i>PLoS ONE</i> , 2010, 5, e14229.	1.1	69
63	Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. <i>Annals of Oncology</i> , 2012, 23, 597-604.	0.6	67
64	FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6856.	1.8	67
65	Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 514-524.	1.2	66
66	Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor β genes on in vitro transformation of human mammary epithelial cells. <i>Molecular Carcinogenesis</i> , 1992, 6, 43-52.	1.3	65
67	Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?. <i>Endocrine-Related Cancer</i> , 2006, 13, 3-6.	1.6	63
68	The role of amphiregulin in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1995, 33, 103-114.	1.1	62
69	Target-based therapies in breast cancer: current status and future perspectives. <i>Endocrine-Related Cancer</i> , 2009, 16, 675-702.	1.6	62
70	Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. <i>Journal of Cellular Physiology</i> , 2004, 198, 31-39.	2.0	61
71	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000132.	2.0	61
72	Immunotherapy in Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 2522.	1.7	60

#	ARTICLE	IF	CITATIONS
73	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Journal of Cellular Physiology</i> , 2006, 208, 344-353.	2.0	59
74	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 845-855.	1.9	58
75	Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. <i>Oncology Reports</i> , 2013, 29, 1763-1768.	1.2	57
76	Treatment of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 257-270.	2.0	57
77	Prognostic value of circulating tumor cellsâ€™™ reduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 314-319.	0.9	56
78	Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. <i>Translational Lung Cancer Research</i> , 2018, 7, 668-677.	1.3	56
79	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2019, 11, 341.	1.7	52
80	The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. <i>Cancer Biology and Therapy</i> , 2013, 14, 1143-1146.	1.5	51
81	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	2.0	51
82	EGF-related peptides in the pathophysiology of the mammary gland. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1997, 2, 143-151.	1.0	49
83	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. <i>BMC Cancer</i> , 2015, 15, 26.	1.1	49
84	Recommendations for the Analysis of ALK Gene Rearrangements in Nonâ€™™Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. <i>Journal of Thoracic Oncology</i> , 2013, 8, 352-358.	0.5	48
85	Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 851-864.	1.0	46
86	Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. <i>Targeted Oncology</i> , 2011, 6, 133-145.	1.7	46
87	Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. <i>Journal of Thoracic Disease</i> , 2019, 11, S113-S126.	0.6	45
88	Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. <i>Journal of Translational Medicine</i> , 2016, 14, 61.	1.8	43
89	Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 486-498.	1.3	43
90	Regulation of human criptoâ€™™1 gene expression by TGFâ€™™Î²1 and BMPâ€™™4 in embryonal and colon cancerâ€™™ cells. <i>Journal of Cellular Physiology</i> , 2008, 215, 192-203.	2.0	42

#	ARTICLE	IF	CITATIONS
91	Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. <i>Current Opinion in Oncology</i> , 2005, 17, 212-217.	1.1	41
92	Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. <i>Pharmacogenomics</i> , 2010, 11, 1169-1179.	0.6	41
93	Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. <i>British Journal of Cancer</i> , 2014, 111, 413-420.	2.9	41
94	Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 25-33.	1.1	40
95	Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. <i>Cell Cycle</i> , 2014, 13, 148-156.	1.3	40
96	EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 2778-2785.	1.2	40
97	Impact of circulating tumor DNA mutant allele fraction on prognosis in KRAS mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 1827-1835.	2.1	40
98	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436.	2.0	40
99	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. <i>International Journal of Cancer</i> , 1999, 80, 589-594.	2.3	39
100	Mini Review. Growth Factors, 2004, 22, 133-139.	0.5	39
101	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 387-396.	1.1	39
102	European Consensus Conference for external quality assessment in molecular pathology. <i>Annals of Oncology</i> , 2013, 24, 1958-1963.	0.6	39
103	External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer. <i>Oncologist</i> , 2015, 20, 257-262.	1.9	39
104	Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells. <i>Journal of Cellular Physiology</i> , 2016, 231, 1514-1521.	2.0	39
105	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.	2.0	38
106	Angiogenesis Inhibitors in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 655316.	1.3	38
107	Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer. <i>Oncotarget</i> , 2013, 4, 1253-1265.	0.8	38
108	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 461-465.	1.1	37

#	ARTICLE	IF	CITATIONS
109	Detection of EGFR Variants in Plasma. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 483-494.	1.2	37
110	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017, 2, e000147.	2.0	36
111	Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. , 1997, 73, 277-282.		35
112	Quercetinâ€s methyl ether inhibits lapatinibâ€s sensitive and â€s resistant breast cancer cell growth by inducing G₂/M arrest and apoptosis. <i>Molecular Carcinogenesis</i> , 2013, 52, 134-143.	1.3	35
113	Expression and functional role of CRIPTO-1 in cutaneous melanoma. <i>British Journal of Cancer</i> , 2011, 105, 1030-1038.	2.9	34
114	Gefitinib inhibits the crossâ€s talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 1135-1144.	1.2	34
115	International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA. <i>BMC Cancer</i> , 2018, 18, 804.	1.1	34
116	RET Inhibitors in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4415.	1.7	34
117	EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. <i>Annals of Oncology</i> , 2000, 11, 319-326.	0.6	33
118	Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0139264.	1.1	33
119	Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. <i>Journal of Cell Science</i> , 2005, 118, 4633-4643.	1.2	32
120	A â€s liveâ€s biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. <i>Lung Cancer</i> , 2009, 65, 123-125.	0.9	32
121	Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	32
122	The International Collaboration for Cancer Classification and Research. <i>International Journal of Cancer</i> , 2021, 148, 560-571.	2.3	32
123	Infection with a transforming growth factor Î± anti-sense retroviral expression vector reduces their vitro growth and transformation of a human colon cancer cell line. <i>International Journal of Cancer</i> , 1993, 54, 952-958.	2.3	31
124	Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. <i>International Journal of Cancer</i> , 1995, 62, 762-766.	2.3	31
125	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 31-37.	0.9	31
126	Recommendations for mutational analysis of EGFR in lung carcinoma. <i>Pathologica</i> , 2010, 102, 119-26.	1.3	31

#	ARTICLE	IF	CITATIONS
127	Aging and the hemopoietic system. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, S3-S12.	2.0	30
128	HER2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2011, 1, 472-474.	7.7	30
129	IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 681-689.	1.4	30
130	Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. <i>Seminars in Cancer Biology</i> , 2022, 84, 293-301.	4.3	30
131	KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment. <i>PLoS ONE</i> , 2011, 6, e29146.	1.1	30
132	A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. <i>Human Pathology</i> , 2011, 42, 1047-1052.	1.1	29
133	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018, 3, e000299.	2.0	29
134	Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Journal of Cellular Physiology</i> , 2005, 205, 355-363.	2.0	28
135	Targeting the EGFR T790M mutation in non-small-cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 159-165.	1.5	28
136	Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF- β 1 and miRNA21 cooperation. <i>PLoS ONE</i> , 2019, 14, e0219597.	1.1	28
137	Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006, 94, 1233-1236.	2.9	27
138	RAS testing in metastatic colorectal cancer: advances in Europe. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 383-396.	1.4	27
139	Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 143-151.	2.0	27
140	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017, 2, e000177.	2.0	27
141	Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. <i>Cancers</i> , 2019, 11, 859.	1.7	27
142	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. <i>Cancer Treatment Reviews</i> , 2013, 39, 489-497.	3.4	26
143	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. <i>Pharmacogenomics</i> , 2015, 16, 1135-1148.	0.6	26
144	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. <i>Cancers</i> , 2020, 12, 2914.	1.7	26

#	ARTICLE	IF	CITATIONS
145	Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. <i>Cancers</i> , 2020, 12, 3804.	1.7	26
146	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	2.0	26
147	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	2.0	26
148	FGFR-targeted therapeutics for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 303-311.	1.9	25
149	Study of Ras Mutationsâ€™™ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. <i>Cancers</i> , 2020, 12, 1919.	1.7	25
150	Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1086-1097.	0.5	25
151	The significance of a Cripto-1-positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics. <i>Cell Cycle</i> , 2013, 12, 1450-1456.	1.3	24
152	Regulation of Cripto-1 Signaling and Biological Activity by Caveolin-1 in Mammary Epithelial Cells. <i>American Journal of Pathology</i> , 2008, 172, 345-357.	1.9	23
153	Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 240, 220-225.	0.5	23
154	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2611.	3.0	22
155	Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. <i>Annals of Oncology</i> , 2012, 23, 2027-2033.	0.6	22
156	Cetuximab in non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 163-175.	1.1	22
157	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 407-420.	1.1	22
158	Higher Quality of Molecular Testing, an Unfulfilled Priority. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 371-377.	1.2	22
159	Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2010, 20, 17-34.	0.4	22
160	RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells. <i>Oncotarget</i> , 2018, 9, 17543-17553.	0.8	22
161	ALK Rearrangement Testing by FISH Analysis in Nonâ€™Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1470-1476.	0.5	21
162	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015, 21, 4153-4164.	3.2	21

#	ARTICLE	IF	CITATIONS
163	Recommendations for the implementation of <i>BRCA</i> testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016, 12, 2071-2075.	1.1	21
164	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018, 9, 17554-17563.	0.8	21
165	Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 42926-42938.	0.8	21
166	Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. <i>Journal of Cellular Physiology</i> , 2002, 190, 74-82.	2.0	20
167	Prognostic Applications of Gene Expression Signatures in Breast Cancer. <i>Oncology</i> , 2009, 77, 2-8.	0.9	20
168	Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 809-813.	1.4	20
169	The role of circulating free DNA in the management of NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 19-28.	1.1	20
170	Transforming growth factor β , amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. <i>International Journal of Oncology</i> , 2002, 21, 941.	1.4	19
171	Gefitinib in Non Small Cell Lung Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-14.	3.0	19
172	Right-sided rhabdoid colorectal tumors might be related to the Serrated Pathway. <i>Diagnostic Pathology</i> , 2013, 8, 31.	0.9	19
173	Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 773-778.	0.5	19
174	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. <i>BMC Cancer</i> , 2018, 18, 828.	1.1	19
175	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540.	0.6	19
176	BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. <i>Cancer Biology and Therapy</i> , 2016, 17, 840-848.	1.5	17
177	Surgery in Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 390.	1.7	17
178	Neuronal Guidance Protein Netrin-1 Induces Differentiation in Human Embryonal Carcinoma Cells. <i>Cancer Research</i> , 2009, 69, 1717-1721.	0.4	16
179	Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. <i>International Journal of Oncology</i> , 2011, 40, 378-84.	1.4	16
180	The prognostic role of circulating tumor cells in lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 859-867.	1.1	16

#	ARTICLE	IF	CITATIONS
181	Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. <i>Molecular and Clinical Oncology</i> , 2017, 7, 113-120.	0.4	16
182	Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 891-900.	1.5	16
183	RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells. <i>Oncotarget</i> , 2014, 5, 10518-10528.	0.8	16
184	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 275-282.	1.1	15
185	Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. <i>Lung Cancer</i> , 2008, 60, 452-454.	0.9	15
186	Activity of Gefitinib in a Non-“Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, e59-e60.	0.5	15
187	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15
188	The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. <i>Journal of Translational Medicine</i> , 2015, 13, 287.	1.8	14
189	Structure-“fluctuation”-function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 410-425.	1.1	14
190	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020, 12, 2948.	1.7	14
191	SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system. <i>Journal of Translational Medicine</i> , 2021, 19, 246.	1.8	14
192	Molecular tests and target therapies in oncology: recommendations from the Italian workshop. <i>Future Oncology</i> , 2021, 17, 3529-3539.	1.1	14
193	Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. <i>IDrugs: the Investigational Drugs Journal</i> , 2010, 13, 636-45.	0.7	14
194	Pharmacokinetic evaluation of zoledronic acid. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 911-918.	1.5	13
195	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1207-1218.	1.1	13
196	The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 683-694.	1.5	13
197	KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting. <i>PLoS ONE</i> , 2014, 9, e85897.	1.1	12
198	Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. <i>Journal of Thoracic Disease</i> , 2019, 11, 1370-1378.	0.6	12

#	ARTICLE	IF	CITATIONS
199	Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1177-1185.	1.5	11
200	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020, 5, e001001.	2.0	11
201	Molecular Markers to Predict Response to Gefitinib: EGFR, ErbB-2, or More?. <i>Journal of Clinical Oncology</i> , 2004, 22, 2035-2036.	0.8	10
202	Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?. <i>Annals of Oncology</i> , 2005, 16, 1709.	0.6	10
203	Osteoblastic metastases in non-small cell lung cancer and its possible significance. <i>Lung Cancer</i> , 2008, 60, 146-147.	0.9	10
204	New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1503-1514.	1.9	10
205	Vandetanib as a potential treatment for breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1295-1303.	1.9	10
206	Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. <i>Translational Lung Cancer Research</i> , 2020, 9, 61-70.	1.3	10
207	Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT). <i>Cancers</i> , 2020, 12, 1627.	1.7	10
208	Gefitinib and Cisplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Simply a Bad Combination?. <i>Journal of Clinical Oncology</i> , 2005, 23, 928-930.	0.8	9
209	Pharmacokinetic evaluation of capecitabine in breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 225-235.	1.5	9
210	Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis. <i>Translational Lung Cancer Research</i> , 2021, 10, 914-925.	1.3	9
211	CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. <i>International Journal of Oncology</i> , 2004, 25, 1013-20.	1.4	9
212	Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer-and lymphokine-activated-killer-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 1992, 34, 272-278.	2.0	8
213	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. <i>Current Opinion in Oncology</i> , 2005, 17, 123-129.	1.1	8
214	Positron Emission Tomography and Circulating Tumor Cells to Monitor a Dramatic Response to Gefitinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, e27-e28.	0.5	8
215	Genomics driven-oncology: challenges and perspectives. <i>BMC Cancer</i> , 2015, 15, 141.	1.1	8
216	External quality assessment for EGFR mutations in Italy: improvements in performances over the time. <i>ESMO Open</i> , 2017, 2, e000160.	2.0	8

#	ARTICLE	IF	CITATIONS
217	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	1.3	8
218	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. <i>Cancers</i> , 2019, 11, 1431.	1.7	7
219	External Quality Assessment Schemes for Biomarker Testing in Oncology. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 736-747.	1.2	7
220	Promising Role of Circulating Tumor Cells in the Management of SCLC. <i>Cancers</i> , 2021, 13, 2029.	1.7	7
221	Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 200-223.	0.5	7
222	Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?. <i>Journal of Clinical Oncology</i> , 2007, 25, 5836-5837.	0.8	6
223	Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. <i>ESMO Open</i> , 2016, 1, e000114.	2.0	6
224	Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development. <i>Translational Lung Cancer Research</i> , 2021, 10, 1444-1456.	1.3	6
225	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	1.7	6
226	Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?. <i>Anticancer Research</i> , 2004, 24, 2985-9.	0.5	6
227	Results of a worldwide external quality assessment of cfDNA testing in lung Cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
228	Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 299-307.	1.1	5
229	Prognostic factor for non-small cell lung cancer with bone metastases at the time of diagnosis. <i>Lung Cancer</i> , 2012, 78, 168.	0.9	5
230	Phase III study with FOLFIRI+ cetuximab versus FOLFIRI+ cetuximab followed by cetuximab alone in <i>RAS</i> and <i>BRAF</i> WT mCRC. <i>Future Oncology</i> , 2018, 14, 1339-1346.	1.1	5
231	The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. <i>Lung Cancer</i> , 2021, 160, 118-126.	0.9	5
232	Abstract 36: The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers.. , 2013, , .		5
233	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
234	Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis. <i>Cancers</i> , 2022, 14, 1934.	1.7	5

#	ARTICLE	IF	CITATIONS
235	Modulation of Epidermal Growth Factor Receptor-Positive Circulating Tumor Cells by Chemotherapy in Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 7746-7748.	0.8	4
236	Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 573-573.	3.0	4
237	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, Volume 4, 1-9.	0.4	4
238	Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site. <i>Cancer Biology and Therapy</i> , 2016, 17, 1089-1093.	1.5	4
239	Pembrolizumab in lung cancer: current evidence and future perspectives. <i>Future Oncology</i> , 2019, 15, 3327-3336.	1.1	4
240	Evolution of <i>RAS</i> testing over time: factors influencing mutation rates in metastatic colorectal cancer patients. <i>Colorectal Cancer</i> , 2020, 9, .	0.8	4
241	Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN) Tj ETQq1 1 0.784314 rgBT /Overlook 479, 1067-1072.	1.4	4
242	Challenges in bioinformatics approaches to tumor mutation burden analysis. <i>Oncology Letters</i> , 2021, 22, 555.	0.8	4
243	COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). <i>ESMO Open</i> , 2021, 6, 100165.	2.0	4
244	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel. <i>Cancer Research</i> , 2014, 74, 3575-3575.	0.4	4
245	Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy. <i>Anticancer Research</i> , 2016, 36, 2119-24.	0.5	4
246	The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 1851.	1.7	4
247	Methodological Issues of Clinical Research with EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 292-302.	0.2	3
248	Osteoblastosis and Activating Epidermal Growth Factor Receptor Mutations: A Relationship?. <i>Journal of Thoracic Oncology</i> , 2010, 5, 415-416.	0.5	3
249	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	1.3	3
250	Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?. <i>Annals of Oncology</i> , 2021, 32, 1311-1313.	0.6	3
251	Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS810-TPS810.	0.8	3
252	Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion. <i>Oncologist</i> , 2022, 27, 7-12.	1.9	3

#	ARTICLE	IF	CITATIONS
253	Endocrine therapy plus zoledronic acid in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2009, 360, 2368-9; author reply 2369-70.	13.9	3
254	A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology. <i>Annals of Oncology</i> , 2007, 18, 960-961.	0.6	2
255	Molecular biology of renal-cell carcinoma. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 30-34.	2.2	2
256	P3.02b-043 Inter-Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1213.	0.5	2
257	Gene methylation in liquid biopsy and risk of recurrence in lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 1286-1289.	0.6	2
258	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 775-783.	1.0	2
259	Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 882-893.	1.2	2
260	Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies. <i>Cancers</i> , 2022, 14, 1052.	1.7	2
261	Zoledronic acid in early-stage breast cancer. <i>Lancet Oncology</i> , The, 2011, 12, 991.	5.1	1
262	Letter to the Editor: Reply to Kobunai <i>et al.</i> . <i>Pharmacogenomics</i> , 2011, 12, 309-310.	0.6	1
263	Comment on "A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens". <i>British Journal of Cancer</i> , 2012, 107, 1791-1792.	2.9	1
264	cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?. <i>EBioMedicine</i> , 2020, 57, 102886.	2.7	1
265	Expression and prognostic significance of the EGFR in solid tumors. , 2008, , 210-223.		1
266	Abstract 3581: Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib. , 2011, , .		1
267	Abstract 2619: Genetic landscape of KRAS-NRAS-BRAF-PIK3CA wild type metastatic colorectal cancer patients enrolled in the CAPRI clinical trial. , 2018, , .		1
268	Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. , 2020, 1, 117-130.		1
269	Circulating Tumor Cells and ctDNA in NSCLC. , 2019, , 465-475.		0
270	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, 270-276.	1.0	0

#	ARTICLE	IF	CITATIONS
271	Cripto. , 2003, , 330-334.		0
272	Breast and Colon Carcinomas: Detection with Plasma CRIPTO-1. , 2008, , 189-202.		0
273	Signal Transduction Inhibitors in the Treatment of Breast Cancer. , 2009, , 177-201.		0
274	Exploration of Targeted Anti-tumor Therapy: a contribution to the development of targeted therapies. , 2020, 1, 1-2.		0